Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer

Br J Cancer. 2016 Sep 6;115(6):655-63. doi: 10.1038/bjc.2016.252. Epub 2016 Aug 18.

Abstract

Background: The degree of histopathological response after neoadjuvant therapy in locally advanced gastric cancer (GC) is a key determinant of patients' long-term outcome. We aimed to assess the pattern of histopathological regression after two neoadjuvant approaches and its impact on survival times.

Methods: Regression grade of the primary tumour (Becker criteria) and the degree of nodal response by a 4-point scale (grades A-D) were assessed. Grade A-true negative lymph nodes (LNs); grade B and C-infiltrated LNs with any or little evidence of nodal response; and grade D-complete pathological response in a previously infiltrated LN. A favourable pathological response was defined as Becker Ia-b and grade D.

Results: From 2004 to 2014, 80 patients with GC (cT3-4/N+ by CT-scan/EUS) were treated with either preoperative chemotherapy (ChT, n=34) or chemoradiation (CRT, n=46). Patients in the CRT group had a higher likelihood of achieving a Becker Ia-b response (58 vs 32%, P=0.001), a grade D nodal regression (30 vs 6%, P=0.009) and a favourable pathological response (23 vs 3%; P=0.019). Patients with a grade D nodal response had a longer 5-year PFS and OS compared with those with a grade B or C response. Patients with a baseline negative LN status had similar outcomes irrespective of the preoperative therapy received (5-year OS; ChT vs CRT, 58 vs 51%, P=0.92).

Conclusions: Preoperative chemoradiation increases the likelihood of achieving favourable histopathological features that correlate with a 5-year OS>70% in GC patients.

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / pathology*
  • Adenocarcinoma / secondary
  • Adenocarcinoma / surgery
  • Adenocarcinoma / therapy
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Asthenia / chemically induced
  • Capecitabine / administration & dosage
  • Chemoradiotherapy*
  • Disease-Free Survival
  • Docetaxel
  • Female
  • Fluorouracil / administration & dosage
  • Gastrectomy
  • Gastrointestinal Diseases / chemically induced
  • Hematologic Diseases / chemically induced
  • Humans
  • Lymphatic Metastasis
  • Male
  • Middle Aged
  • Neoadjuvant Therapy / methods*
  • Neoplasm Grading
  • Organoplatinum Compounds / administration & dosage
  • Oxaliplatin
  • Paclitaxel / administration & dosage
  • Radiotherapy, Conformal* / adverse effects
  • Radiotherapy, Intensity-Modulated* / adverse effects
  • Retrospective Studies
  • Stomach Neoplasms / drug therapy
  • Stomach Neoplasms / pathology*
  • Stomach Neoplasms / surgery
  • Stomach Neoplasms / therapy
  • Taxoids / administration & dosage
  • Treatment Outcome

Substances

  • Organoplatinum Compounds
  • Taxoids
  • Oxaliplatin
  • Docetaxel
  • Capecitabine
  • Paclitaxel
  • Fluorouracil